Tags

Type your tag names separated by a space and hit enter

Bone health and vitamin D status in young epilepsy patients on valproate monotherapy.
Clin Neurol Neurosurg. 2016 Jul; 146:52-6.CN

Abstract

OBJECTIVE

To evaluate bone health and vitamin D adequacy in a cohort of epilepsy patients on chronic valproate (VPA) monotherapy.

METHODS

Bone mineral density (BMD) using dual X-ray absorptiometry and serum concentrations of 25-hydroxyvitamin D, parathyroid hormone, calcium, phosphorus, and alkaline phosphatase were measured in 50 young adult epilepsy patients on VPA monotherapy and 50 age, sex and socioeconomically matched healthy subjects.

RESULTS

Mean age of epilepsy patients was 26±7.2 (±SD) years, and females constituted 66%. Significantly lower mean lumbar spine and femoral neck BMDs (g/cm(2)) and lower femoral neck Z-score were observed in epilepsy patients in comparison with controls. Prevalence of low BMD (Z-score ≤-2.0) was 26% and 10% at lumbar spine, and 10% and 4% at femoral neck in epileptic and control groups respectively. No correlation was found between duration or dosage of VPA and BMDs. Vitamin D deficiency (≤20ng/ml) was highly prevalent (>90%) in epilepsy patients and controls.

CONCLUSION

Chronic VPA therapy is associated with lower BMD measurements in young epilepsy patients. Hypovitaminosis D is highly prevalent in general population.

PRACTICE IMPLICATIONS

Prophylactic and therapeutic strategies against osteoporosis should be implemented in VPA-treated patients. Routine evaluation for bone disease by measuring BMD and supplementation of calcium and vitamin D can allow effective treatment of epilepsy without bone adverse effects.

Authors+Show Affiliations

Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Damascus, Damascus, Syria.Department of Internal Medicine, School of Medicine, University of Damascus, Damascus, Syria.Department of Internal Medicine, School of Medicine, University of Damascus, Damascus, Syria.Department of Pharmaceutics and Pharmaceutical Technology, School of Pharmacy, University of Damascus, Damascus, Syria. Electronic address: ylama@hotmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27150607

Citation

Albaghdadi, Ola, et al. "Bone Health and Vitamin D Status in Young Epilepsy Patients On Valproate Monotherapy." Clinical Neurology and Neurosurgery, vol. 146, 2016, pp. 52-6.
Albaghdadi O, Alhalabi MS, Alourfi Z, et al. Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clin Neurol Neurosurg. 2016;146:52-6.
Albaghdadi, O., Alhalabi, M. S., Alourfi, Z., & Youssef, L. A. (2016). Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. Clinical Neurology and Neurosurgery, 146, 52-6. https://doi.org/10.1016/j.clineuro.2016.04.019
Albaghdadi O, et al. Bone Health and Vitamin D Status in Young Epilepsy Patients On Valproate Monotherapy. Clin Neurol Neurosurg. 2016;146:52-6. PubMed PMID: 27150607.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Bone health and vitamin D status in young epilepsy patients on valproate monotherapy. AU - Albaghdadi,Ola, AU - Alhalabi,Mohammad Salem, AU - Alourfi,Zaynab, AU - Youssef,Lama A, Y1 - 2016/04/26/ PY - 2015/05/14/received PY - 2016/01/28/revised PY - 2016/04/25/accepted PY - 2016/5/7/entrez PY - 2016/5/7/pubmed PY - 2017/3/11/medline KW - Bone mineral density KW - Epilepsy KW - Valproate KW - Vitamin D SP - 52 EP - 6 JF - Clinical neurology and neurosurgery JO - Clin Neurol Neurosurg VL - 146 N2 - OBJECTIVE: To evaluate bone health and vitamin D adequacy in a cohort of epilepsy patients on chronic valproate (VPA) monotherapy. METHODS: Bone mineral density (BMD) using dual X-ray absorptiometry and serum concentrations of 25-hydroxyvitamin D, parathyroid hormone, calcium, phosphorus, and alkaline phosphatase were measured in 50 young adult epilepsy patients on VPA monotherapy and 50 age, sex and socioeconomically matched healthy subjects. RESULTS: Mean age of epilepsy patients was 26±7.2 (±SD) years, and females constituted 66%. Significantly lower mean lumbar spine and femoral neck BMDs (g/cm(2)) and lower femoral neck Z-score were observed in epilepsy patients in comparison with controls. Prevalence of low BMD (Z-score ≤-2.0) was 26% and 10% at lumbar spine, and 10% and 4% at femoral neck in epileptic and control groups respectively. No correlation was found between duration or dosage of VPA and BMDs. Vitamin D deficiency (≤20ng/ml) was highly prevalent (>90%) in epilepsy patients and controls. CONCLUSION: Chronic VPA therapy is associated with lower BMD measurements in young epilepsy patients. Hypovitaminosis D is highly prevalent in general population. PRACTICE IMPLICATIONS: Prophylactic and therapeutic strategies against osteoporosis should be implemented in VPA-treated patients. Routine evaluation for bone disease by measuring BMD and supplementation of calcium and vitamin D can allow effective treatment of epilepsy without bone adverse effects. SN - 1872-6968 UR - https://www.unboundmedicine.com/medline/citation/27150607/Bone_health_and_vitamin_D_status_in_young_epilepsy_patients_on_valproate_monotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0303-8467(16)30153-6 DB - PRIME DP - Unbound Medicine ER -